The Food and Drug Administration (FDA) has approved the first drug to treat double chin that can eliminate neck fat in most people without surgery.
Kybella, commercial name of the drug is a deoxycholic acid made by Californa's Kythera Biopharmaceuticals based in Westlake Village, California.
Get Rid of 'Double Chin' With a Fat-Busting Jab
A new fat-busting injection that promises to get rid of unsightly fat around the jaw line without having to resort to surgery or dieting could be a revolutionary treatment.
Advertisement
Deoxycholic acid is a naturally occurring molecule in the body that helps to absorb fat. A licensed dermatologist can inject the drug under the jawline right into the fat tissue; the procedure takes only a few minutes. The drug destroys the cell membrane of submental fat, causing it to burst. It takes two to three days to heal.
According to a survey by the American Society for Dermatologic Surgery in 2014, about 68 percent of people were concerned about excess fat under the chin and neck. Kybella will be commercially available in June.
![Get Rid of Your Double Chin Without Surgery]( "Get Rid of Your Double Chin Without Surgery")
The Food and Drug Administration advisory committee recently, unanimously approved of a new drug injection that can help people get rid of their double chin with a single jab.
Kybella was approved after the manufacturer submitted 19 clinical studies involving nearly 2,600 patients. The clinical tests showed that kybella worked to eliminate moderate to severe chin fat.
Currently, surgery was the only other way to eliminate double chin with traditional liposuction.
According to the FDA, the most common side effects of Kybella are swelling, bruising, pain, numbness, redness and hardness in the treatment area.
"It is important to remember that Kybella is only approved for the treatment of fat occurring below the chin, and it is not known if Kybella is safe or effective for treatment outside of this area," said, Dr. Amy G. Egan, deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research.
Source: Medindia
Get Rid of Your Double Chin Without Surgery
The Food and Drug Administration advisory committee recently, unanimously approved of a new drug injection that can help people get rid of their double chin with a single jab.
Advertisement
Kybella was approved after the manufacturer submitted 19 clinical studies involving nearly 2,600 patients. The clinical tests showed that kybella worked to eliminate moderate to severe chin fat.
Currently, surgery was the only other way to eliminate double chin with traditional liposuction.
According to the FDA, the most common side effects of Kybella are swelling, bruising, pain, numbness, redness and hardness in the treatment area.
"It is important to remember that Kybella is only approved for the treatment of fat occurring below the chin, and it is not known if Kybella is safe or effective for treatment outside of this area," said, Dr. Amy G. Egan, deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research.
Source: Medindia
Animal Cell Jabs to Remove Double Chins
Dieters could lose their double chins and spare tyres by getting injections of heat-producing cells, say researchers. Heat-producing cells are commonly found in animals and babies.
Advertisement
 Pharma Giant Bayer Tests 'Double Chin' DrugGerman drugs giant Bayer said Monday it had launched tests into an injectable drug to combat the fat deposits that lead to the dreaded double chin. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.